Aug. 3 at 12:20 AM
$ARCT I dearly hold Biogen (BIIB), LLY, PFE, and Neurocrine Biosciences (NBIX). On Friday the president said a dreadful final word to biotechs "cut your prescription drug price." PFE and LLY folded. But BIIB and NBIX snapped out of drench. PFE and LLY have some cancer and weight loss programs. Oncology drug prices you definitely have to cut. Weight loss phill leaves so much wrinkles on the skin after losing extra grams...That skin care problem is creating another controversial issues other than price cuts and on insurance coverage pressures. But rare disease you have no other way around to ask for discounts. In particular BIogen Spinal Muscular atrophy (SMA) saw rising demand and raised guidance. I think rare disease thrive, more so with successful gene therapy/editing program.
